合并后公司拥有以景助达及GB491治疗晚期或转移性HR+/HER2-乳腺癌的协同专营权。本文为IPO早知道原创作者|罗宾微信公众号|ipozaozhidao据IPO早知道消息,据嘉和生物(6998.HK)于4月15日晚间公告,公司已向港交所递交上市申请,亿腾医药将反向收购嘉和生物,摩根士丹利和浦银国际为此次新上市申请的联席保荐人。2020年、2021年及2023年,亿腾医药4次向港交所提交上市申请...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.